FDA Approves Breakthrough Drug Rasonque for Metastatic Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib), a groundbreaking new drug to treat metastatic pancreatic cancer. Photo courtesy of Revolution Medicines The FDA approved Rasonque, a new drug to treat the most common type of pancreatic cancer. A clinical trial found that those who received Rasonque had more than double the average survival rate: around 13 months compared to just over 6 months with…
The FDA has approved Rasonque, a new drug designed to fight metastatic pancreatic cancer, the sixth-leading cause of cancer-related deaths worldwide. In a clinical trial, patients receiving Rasonque experienced a significantly longer average survival of 13.2 months, compared to 6.7 months for those treated with chemotherapy alone.
Rasonque targets a specific protein called RAS, which is responsible for driving the growth and spread of pancreatic cancer cells. Unlike traditional chemotherapy, Rasonque is a once-daily oral pill that works to neutralize the cancer-driving signals, ultimately causing the cancer cells to die. Experts are optimistic about the drug's potential, as it represents a significant advancement in the treatment of a deadly form of cancer.
Written by urgent.news from Healthline News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
